tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Nail Diseases D009260 2 associated lipids
Paronychia D010304 3 associated lipids
Duodenal Ulcer D004381 12 associated lipids
Dyspnea D004417 10 associated lipids
Vascular Diseases D014652 16 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Listeriosis D008088 12 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Ascites D001201 25 associated lipids
Albuminuria D000419 18 associated lipids
Anemia D000740 21 associated lipids
Osteomalacia D010018 5 associated lipids
Tremor D014202 15 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Vasculitis D014657 14 associated lipids
Hypothermia D007035 19 associated lipids
Parkinson Disease D010300 53 associated lipids
Down Syndrome D004314 18 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Keloid D007627 12 associated lipids
Nephritis D009393 19 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Respiration Disorders D012120 5 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Facial Neoplasms D005153 3 associated lipids
Dysgammaglobulinemia D004406 3 associated lipids
Influenza, Human D007251 11 associated lipids
Immune System Diseases D007154 3 associated lipids
Headache D006261 4 associated lipids
Cystitis D003556 23 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
HIV Infections D015658 20 associated lipids
Drug Eruptions D003875 30 associated lipids
Folliculitis D005499 7 associated lipids
Blindness D001766 6 associated lipids
Oliguria D009846 2 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Dermatitis, Allergic Contact D017449 20 associated lipids
Graves Disease D006111 6 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Gout D006073 4 associated lipids
Papillomavirus Infections D030361 4 associated lipids
Choline Deficiency D002796 16 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Biliary Fistula D001658 13 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Renal Insufficiency D051437 8 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Conde M et al. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. 1995 Immunology pmid:7538492
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Goldfeld AE et al. Cyclosporin A and FK506 block induction of the Epstein-Barr virus lytic cycle by anti-immunoglobulin. 1995 Virology pmid:7538254
Galat A and Metcalfe SM Peptidylproline cis/trans isomerases. 1995 Prog. Biophys. Mol. Biol. pmid:7538221
Hamasaki Y et al. Inhibition of leukotriene production by FK506 in rat basophilic leukemia-1 cells. 1995 Pharmacology pmid:7538218
Lee TK et al. Postoperative selective bowel decontamination prevents gram-negative bacterial translocation in small-bowel graft recipients. 1995 J. Surg. Res. pmid:7538186
Mills RA et al. Topical FK-506 prevents experimental corneal allograft rejection. 1995 Cornea pmid:7538061
Woodle ES et al. FK 506 rescue therapy for hepatic allograft rejection: experience with an aggressive approach. 1995 Clin Transplant pmid:7537988
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Miyazawa H et al. Hamster to rat kidney xenotransplantation. Effects of FK 506, cyclophosphamide, organ perfusion, and complement inhibition. 1995 Transplantation pmid:7537396
Torii N et al. An inhibitor for calcineurin, FK506, blocks induction of long-term depression in rat visual cortex. 1995 Neurosci. Lett. pmid:7537357
Koch K et al. The C-32 triacetyl-L-rhamnose derivative of ascomycin: a potent, orally active macrolactone immunosuppressant. 1995 J. Med. Chem. pmid:7537331
Tanida I et al. Cooperation of calcineurin and vacuolar H(+)-ATPase in intracellular Ca2+ homeostasis of yeast cells. 1995 J. Biol. Chem. pmid:7537264
Osman A et al. Schistosoma mansoni: characterization of p50, an immunophilin. 1995 Exp. Parasitol. pmid:7537219
Hisatomi K et al. Effect of dose of cyclosporine or FK506 and antithrombotic agents on cardiac allograft vascular disease in heterotopically transplanted hearts in rats. 1995 Jan-Feb J. Heart Lung Transplant. pmid:7537098
Iwabuchi T et al. Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth. 1995 J. Dermatol. Sci. pmid:7537082
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Arita S et al. Effect of FK 506 in experimental pancreas transplantation. 1995 Transplant. Proc. pmid:7536980
Büttemeyer R et al. Peripheral nerve allotransplant immunosuppressed with FK 506: preliminary results. 1995 Transplant. Proc. pmid:7536979
Ito A et al. Induction of tolerance in rat cardiac allograft model by intrathymic injection of donor bone marrow cells. 1995 Transplant. Proc. pmid:7536974
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Masaki Y et al. Cellular basis of immunologic tolerance following total bowel transplantation in rats. II. Dominant role of suppressor T cells in adoptive transfer of acquired tolerance to vascularized allografts. 1995 Transplant. Proc. pmid:7536972
Masaki Y et al. Cellular basis of acquired immunologic tolerance following total bowel transplantation in rats. I. Relation between donor lymphocyte chimerism and host-cell-mediated immunity. 1995 Transplant. Proc. pmid:7536971
Bierer BE Biology of cyclosporin A and FK506. 1994 Prog. Clin. Biol. Res. pmid:7536944
Bang H et al. Activation of Ca2+ signaling in neutrophils by the mast cell-released immunophilin FKBP12. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536932
Wortis HH et al. B-cell activation by crosslinking of surface IgM or ligation of CD40 involves alternative signal pathways and results in different B-cell phenotypes. 1995 Proc. Natl. Acad. Sci. U.S.A. pmid:7536930
Lyons WE et al. Neuronal regeneration enhances the expression of the immunophilin FKBP-12. 1995 J. Neurosci. pmid:7536825
Min Z and Jones NF Limb transplantation in rats: immunosuppression with FK-506. 1995 J Hand Surg Am pmid:7536766
Schwaninger M et al. Involvement of the Ca(2+)-dependent phosphatase calcineurin in gene transcription that is stimulated by cAMP through cAMP response elements. 1995 J. Biol. Chem. pmid:7536740
Marumo T et al. Cyclosporin A inhibits nitric oxide synthase induction in vascular smooth muscle cells. 1995 Hypertension pmid:7536714
Kuwano K and Arai S The inhibitory effect of FK506 on cytotoxic T-lymphocyte killing. 1994 Immunol. Lett. pmid:7536706
Iwasaki K et al. Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506. 1995 Drug Metab. Dispos. pmid:7536652
Bronster DJ et al. Demyelinating sensorimotor polyneuropathy after administration of FK506. 1995 Transplantation pmid:7535959
Shaffer D et al. Normal pancreas allograft function following simultaneous pancreas kidney transplantation after rescue therapy with tacrolimus (FK506). 1995 Transplantation pmid:7535958
Atkison P et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. 1995 Lancet pmid:7535875
Jiang H et al. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. 1995 J. Invest. Dermatol. pmid:7535825
Grimmond S et al. Exclusion of the 13-kDa rapamycin binding protein gene (FKBP2) as a candidate gene for multiple endocrine neoplasia type 1. 1995 Hum. Genet. pmid:7535744
Ikeda H and Fujiwara K Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro. 1995 Hepatology pmid:7535735
Thomson AW Immunosuppressive drugs and the induction of transplantation tolerance. 1994 Transpl. Immunol. pmid:7535641
Bakhtiar R and Stearns RA Studies on non-covalent associations of immunosuppressive drugs with serum albumin using pneumatically assisted electrospray ionization mass spectrometry. 1995 Rapid Commun. Mass Spectrom. pmid:7535601
Hadley S et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. 1995 Transplantation pmid:7535482
Hirose M and Kuroda Y Reinforcement of cyclosporin A-induced red cell destruction by superoxide. 1994 Tokushima J. Exp. Med. pmid:7535479
Charters AR et al. The subcellular distribution of FK506 binding proteins in rat brain. 1994 Biochem. Soc. Trans. pmid:7535259
Charters AR et al. Immunochemical analysis of FK506 binding proteins in neuronal cell lines and rat brain. 1994 Biochem. Soc. Trans. pmid:7535258
Jusko WJ et al. Pharmacokinetics of tacrolimus in liver transplant patients. 1995 Clin. Pharmacol. Ther. pmid:7535213
Woo J et al. Combined effects of FK506 (tacrolimus) and cyclophosphamide on atypical B220+ T cells, cytokine gene expression and disease activity in MRL/MpJ-lpr/lpr mice. 1995 Clin. Exp. Immunol. pmid:7535208
Komori T [The change of lymphocyte subset and effect of FK506 in experimental small bowel transplantation of rats]. 1995 Nihon Geka Gakkai Zasshi pmid:7534867
Sen J et al. Expression and induction of nuclear factor-kappa B-related proteins in thymocytes. 1995 J. Immunol. pmid:7534792
Swenson JM et al. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506. 1995 J. Am. Coll. Cardiol. pmid:7534779
Molenaar JC [Transplantation of the small intestine]. 1995 Ned Tijdschr Geneeskd pmid:7534380
Gonschior AK et al. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA). 1994 Br J Clin Pharmacol pmid:7534100
Egawa H et al. Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. 1995 Transplantation pmid:7533958
Gregory CR et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. 1995 Transplantation pmid:7533955
Dawson TM et al. Nitric oxide: cellular regulation and neuronal injury. 1994 Prog. Brain Res. pmid:7533914
Hirakata Y et al. Influence of various immunosuppressive agents on the occurrence of endogenous bacteraemia in mice. 1995 J. Med. Microbiol. pmid:7533840
Bundick RV et al. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. 1995 Clin. Exp. Immunol. pmid:7533681
Hanafusa T et al. Long-term impact of hepatitis virus infection on kidney transplant recipients and a pilot study of the effects of interferon alpha on chronic hepatitis C. 1995 Transplant. Proc. pmid:7533440
Scantlebury VP et al. Renal transplantation under cyclosporine and FK 506 for hemolytic uremic syndrome. 1995 Transplant. Proc. pmid:7533436
Ochiai T et al. Phase III study of FK 506 in kidney transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533435
Sakamoto K et al. Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration. 1995 Transplant. Proc. pmid:7533434
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Shapiro R et al. A prospective, randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone in renal transplant patients. 1995 Transplant. Proc. pmid:7533432
Laskow DA et al. Phase II FK 506 multicenter concentration control study: one-year follow-up. 1995 Transplant. Proc. pmid:7533431
Funayama Y et al. Changes in cell adhesion molecules after small bowel transplantation in rats. 1995 Transplant. Proc. pmid:7533426
Izutani H et al. Graft coronary arteriosclerosis in rat heart transplant model with FK 506 short-term administration. 1995 Transplant. Proc. pmid:7533425
Kumano K et al. Role of endothelin in FK 506-induced renal hypoperfusion in rats. 1995 Transplant. Proc. pmid:7533423
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Tashiro H et al. Monitoring for engraftment of rat orthotopic liver transplantation by semiquantitative PCR. 1995 Transplant. Proc. pmid:7533421
Saito S et al. The pattern of rejection and susceptibility to different kinds of immunosuppression after combined liver, duodenum, and pancreas transplantation in swine--immunosuppressive drugs versus ex vivo immunomodulation of the allograft. 1995 Transplant. Proc. pmid:7533420
Ochiai T et al. Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group. 1995 Transplant. Proc. pmid:7533419
Bismuth H Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group. 1995 Transplant. Proc. pmid:7533415
Jiang H et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. 1995 Transplant. Proc. pmid:7533413
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Tanabe M et al. Therapeutic synergism between low-dose FK 506 and antimetabolites in rat allogeneic heart transplantation. 1995 Transplant. Proc. pmid:7533411
Kawano K et al. Protective effect of FK 506 on hepatic injury following cold ischemic preservation and transplantation: influence on hepatic microcirculation. 1995 Transplant. Proc. pmid:7533410
Tamura K et al. Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high. 1995 Transplant. Proc. pmid:7533409
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Fukuzaki T et al. Induction of unresponsiveness to islet allografts with donor spleen cell inoculation followed by a single injection of FK 506. 1995 Transplant. Proc. pmid:7533407
Ko S et al. Significance of newly developed liposomal FK 506 in canine liver transplantation. 1995 Transplant. Proc. pmid:7533406
Kuroki H and Ikuta Y Nerve regeneration of vascularized rat limb allograft and functional recovery of long-term graft survivals treated by short course of FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533405
Celli S et al. Mechanisms of protection from humoral rejection by a xenografted liver. 1995 Transplant. Proc. pmid:7533395
Sakimoto H et al. Prolonged survival of hamster-to-rat pancreas xenografts by FK 506 and splenectomy. 1995 Transplant. Proc. pmid:7533394
Tsugita M et al. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. 1995 Transplant. Proc. pmid:7533393
Tanaka M et al. Effect of anticomplement agent K-76 COOH in hamster-to-rat and guinea pig-to-rat xenotransplantation. 1995 Transplant. Proc. pmid:7533392
Wennberg L et al. Efficacy of various immunosuppressive drugs in preventing pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:7533391
Watanabe K et al. Factors influencing long-term operational tolerance in dogs treated with fractionated lymphoid irradiation, donor bone marrow cell infusion and FK506. 1995 Transplant. Proc. pmid:7533389
Zeevi A et al. Serial evaluation of immune profiles of simultaneous bone marrow and whole organ transplant recipients. 1995 Transplant. Proc. pmid:7533388
Murase N et al. Bone marrow augmentation for heart, liver, and small bowel transplantation: prolongation of graft survival and incidence of graft-versus-host disease. 1995 Transplant. Proc. pmid:7533386
Fay JW et al. FK 506-based immunosuppression for prevention of graft versus host disease after unrelated donor marrow transplantation. 1995 Transplant. Proc. pmid:7533383
Teraoka S et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. 1995 Transplant. Proc. pmid:7533381
Barkholt LM et al. New criteria for diagnosing cytomegalovirus hepatitis in liver transplant patients. 1995 Transplant. Proc. pmid:7533375
Vargas V et al. Alpha-interferon for acute hepatitis C in liver transplant patients. 1995 Transplant. Proc. pmid:7533374
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Martinez OM et al. Molecular markers of Epstein-Barr virus infection in the circulation of transplant recipients. 1995 Transplant. Proc. pmid:7533372
Armstrong VW et al. Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. 1995 Transplant. Proc. pmid:7533371
Gaweco AS et al. Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. 1995 Transplant. Proc. pmid:7533370
O'Rourke M et al. Recovery of delayed-type hypersensitivity following liver transplantation. 1995 Transplant. Proc. pmid:7533369
Lang T et al. Distinct patterns of Th2 cytokine production during immune activation in pediatric liver allograft recipients. 1995 Transplant. Proc. pmid:7533367